Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 2,277 shares at $22.19 ($51K) on 2026-01-13, disclosed to the SEC on 2026-01-15.
Seasonal sale ($51k) by Chief Scientific Officer — this insider has traded APLS in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-23 | $240K | — | Filing → |
| APLS | SELL | 2025-01-21 | $22K | — | Filing → |